Related Experiment Video
Updated: Apr 13, 2026

Intraductal Delivery to the Rabbit Mammary Gland
Published on: March 9, 2017
Disruptive innovation in breast cancer therapeutic development
Sridatta V Teerdhala1, Hannah L Chang2, Isaac S Chan3
1Department of Internal Medicine, Division of Hematology and Oncology, University of Texas Southwestern, Dallas, TX, USA.
None:
Therapeutic development by nature is disruptive. By applying Christensen's disruptive innovation framework, we analyze why mutation-anchored agents somtimes underperform, why broadly acting therapies succeed as disruptive therapies, and how host-driven, subtype-agnostic modalities, such as immunotherapy, antibody-drug conjugates, and cell and gene therapies, offer a blueprint for scalable and durable clinical and commercial impact.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targeted Cancer Therapies
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers
Treatment Resistent Cancers

